SCHEMBL19123778

SCHEMBL19123778

CC/C=C\C/C=C\C/C=C\CCCCCCCC(=O)OCC(C)COC(=O)CCCCCCC/C=C\C/C=C\C/C=C\CC

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.73
CYP3A4 P08684 2/20 0.73
ALOX15 P16050 2/20 0.73
HSD17B10 Q99714 2/20 0.73
TDP1 Q9NUW8 2/20 0.73
TSHR P16473 1/20 0.73
NR1I2 O75469 2/20 0.63
PTGS2 P35354 2/20 0.63
PGR P06401 1/20 0.63
ADORA3 P0DMS8 1/20 0.63
PDE4D Q08499 1/20 0.63
F7 P08709 2/20 0.58
F3 P13726 2/20 0.58
MAPT P10636 2/20 0.58
CYP19A1 P11511 2/20 0.58
OXER1 Q8TDS5 1/20 0.58
KDM4E B2RXH2 1/20 0.58
MEN1 O00255 1/20 0.58
FFAR1 O14842 1/20 0.58
LMNA P02545 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31493835 0.96 ALDH1A1 (0.68) ALDH1A1CYP3A4ALOX15HSD17B10TDP1
SCHEMBL1413230 0.93 ALDH1A1 (0.75) ALDH1A1CYP3A4ALOX15HSD17B10TDP1
SCHEMBL19123572 0.91 FAAH (0.67) ALDH1A1CYP3A4ALOX15HSD17B10TDP1
SCHEMBL27796185 0.90 ALDH1A1 (0.71) ALDH1A1CYP3A4ALOX15HSD17B10TDP1
SCHEMBL1173005 0.90 ALDH1A1 (0.71) ALDH1A1CYP3A4ALOX15HSD17B10TDP1
SCHEMBL18204270 0.88 DGKA (0.62) ALDH1A1CYP3A4ALOX15HSD17B10TDP1
SCHEMBL18204271 0.88 DGKA (0.62) ALDH1A1CYP3A4ALOX15HSD17B10TDP1
SCHEMBL3195987 0.88 ALDH1A1 (0.73) ALDH1A1CYP3A4ALOX15HSD17B10TDP1
SCHEMBL12437840 0.88 ALDH1A1 (0.67) ALDH1A1CYP3A4ALOX15HSD17B10TDP1
SCHEMBL6898815 0.88 ALDH1A1 (0.67) ALDH1A1CYP3A4ALOX15HSD17B10TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4223285-A2 METHOD OF ENCAPSULATING A NUCLEIC ACID IN A LIPID NANOPARTICLE HOST Novartis AG (CH) 2023-08-09 EP disclosed
EP-3169309-B1 METHOD OF ENCAPSULATING A NUCLEIC ACID IN A LIPID NANOPARTICLE HOST NOVARTIS AG (CH) 2023-05-10 EP disclosed
EP-4019506-A1 LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS Novartis AG (CH) 2022-06-29 EP disclosed
EP-3083579-B1 LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS NOVARTIS AG (CH) 2022-01-26 EP disclosed
US-20170196809-A1 METHOD OF ENCAPSULATING A NUCLEIC ACID IN A LIPID NANOPARTICLE HOST NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. 2017-07-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170196809-A1 METHOD OF ENCAPSULATING A NUCLEIC ACID IN A LIPID NANOPARTICLE HOST POLN, POLRMT, RNGTT ALDH1A1 2314/4885CYP3A4 4471/4885ALOX15 490/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.